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Abstract: Autophagy is an ancient, intracellular degradative system which plays important 
roles in regulating protein homeostasis and which is essential for survival when cells are faced 
with metabolic stress. Increasing evidence suggests that autophagy also functions as a tumor 
suppressor mechanism that harnesses the growth and/or survival of cells as they transition 
towards a rapidly dividing malignant state. However, the impact of autophagy on cancer pro-
gression and on the efﬁ  cacy of cancer therapeutics is controversial. In particular, although the 
induction of autophagy has been reported after treatment with a number of therapeutic agents, 
including imatinib, this response has variously been suggested to either impair or contribute 
to the effects of anticancer agents. More recent studies support the notion that autophagy 
compromises the efﬁ  cacy of anticancer agents, where agents such as chloroquine (CQ) that 
impair autophagy augment the anticancer activity of histone deacetylase (HDAC) inhibitors and 
alkylating agents. Inhibition of autophagy is a particularly attractive strategy for the treatment of 
imatinib-refractory chronic myelogenous leukemia (CML) since a combination of CQ with the 
HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) compromises the survival of even 
BCR-ABL-T315I+ imatinib-resistant CML. Additional studies are clearly needed to establish 
the clinical utility of autophagy inhibitors and to identify patients most likely to beneﬁ  t from 
this novel therapeutic approach.
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Autophagy and its role in cancer
Autophagy is an evolutionarily conserved bulk protein degradative pathway in which 
double-membraned autophagosome vesicles engulf target proteins or organelles and 
deliver them to lysosomes where they are degraded. Accordingly, the autophagic 
response plays important roles in regulating protein and organelle homeostasis. 
However, this pathway is also essential to generate alternative energy sources dur-
ing starvation or other states of signiﬁ  cant cellular stress (Klionsky and Emr 2000; 
Yorimitsu and Klionsky 2005). Further, mouse knockout models have demonstrated 
that autophagy also plays a critical role in mammalian development, where targeted 
deletion of Beclin-1 leads to mid-gestational embryonic lethality (Yue et al 2003) and 
where loss of either Atg5 or Atg7, two key players in the ubiquitin-like systems of this 
pathway, results in perinatal lethality (Kuma et al 2004; Komatsu et al 2005).
Several recent high-proﬁ  le investigations have established that autophagy also plays 
important roles in cancer biology. However, exactly how autophagy intersects with can-
cer development, disease progression, tumor maintenance, and therapeutic responses is 
controversial. The most signiﬁ  cant studies regarding the role(s) of autophagy in cancer 
were recently reviewed by White and colleagues (Mathew et al 2007). Collectively, 
studies in this arena indicate that autophagy is a tumor suppressor pathway that holds Biologics: Targets & Therapy 2008:2(2) 202
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cancer development in check, by preventing the proliferation of 
altered cells. For example, mice haploinsufﬁ  cient for Beclin-1, 
an established initiator of the autophagy pathway, are tumor 
prone (Liang et al 1999; Qu et al 2003; Yue et al 2003). Further, 
allelic loss of Beclin-1 is a frequent event in certain types of 
solid tumors and genes encoding other autophagy regulators 
are localized to “hot spots” for deletions in tumors (Aita 
et al 1999; Liang et al 1999). Thus, impairing the autophagy 
response may prime cells for oncogenesis and contribute to 
the intrinsic genetic instability of pre-malignant and cancer 
cells. Considering this, agents that stimulate autophagy have 
potential value in cancer chemoprevention.
Paradoxically, it appears that activation of autophagy is 
detrimental once a cancer has fully developed. In particular, 
the degradation of cytoplasmic material and organelles by 
autophagy is essential to prevent bioenergetic failure when 
tumor cells face nutrient or oxygen deprivation (Lum et al 
2005a), which are hallmarks of the tumor microenvironment. 
Thus, here autophagy would be predicted to promote tumor 
cell survival and consequently, disease progression (Lum 
et al 2005b). Indeed, despite their diverse mechanisms of 
action, many frontline anticancer agents ultimately shut down 
conventional metabolic pathways due to the cellular stress 
that they impose, and they thus can stimulate autophagy. 
Indeed, the induction of autophagy has been observed in 
malignant cells after treatment with a number of cancer 
therapeutics including arsenic trioxide, rapamycin, histone 
deacetylase (HDAC) inhibitors, tamoxifen, imatinib, and 
ionizing radiation (Bursch et al 1996; Paglin et al 2001; 
Kanzawa et al 2003; Shao et al 2004; Takeuchi et al 2005; 
Ertmer et al 2007). Although some of the these studies have 
suggested that efﬁ  cacy of these agents correlates with their 
ability to stimulate autophagy-mediated cell death, such 
conclusions need rigorous testing, especially since these 
modalities also trigger apoptosis. In fact, two recent studies 
have shown that combining inhibitors of autophagy with 
alkylating agents or HDAC inhibitors signiﬁ  cantly enhances 
their anticancer activity (Amaravadi et al 2007; Carew et al 
2007). Collectively, the majority of investigations have 
shown that apoptosis is a much more efﬁ  cient mode of cell 
death than autophagy-mediated cell killing.
Inhibition of autophagy as 
a therapeutic strategy for 
imatinib-refractory CML
Chronic myelogenous leukemia (CML) is one of the four 
most common types of adult leukemia. In contrast to most 
forms of cancer, the molecular basis of disease development 
and pathogenesis is very well deﬁ  ned for CML. The under-
lying cause of CML is the formation of the Philadelphia 
chromosome due to a translocation between chromosomes 
9 and 22. This translocation results in the production of the 
BCR-ABL fusion protein, a tyrosine kinase that controls 
critical signaling pathways involved in the development and 
progression of CML. The disease is subdivided into three 
phases, chronic phase, accelerated phase, and blast crisis, 
and disease progression can occur over several years.
Treatment of CML was revolutionized by the advent of 
imatinib mesylate (Gleevec™; Novartis), a targeted agent 
that inhibits the tyrosine kinase activity of BCR-ABL by 
competing with ATP for binding to the active site of the 
enzyme. Imatinib is very effective for many CML patients 
particularly during the chronic phase, yet drug resistance is 
an emerging problem. Several factors contribute to clinical 
imatinib resistance, including BCR-ABL overexpression 
and gene ampliﬁ  cation and/or loss-of-function mutations 
in p53 (Shah et al 2002; Wendel et al 2006). However, the 
most prevalent cause of drug resistance is the development 
of missense mutations in BCR-ABL that either precludes 
the adoption of the inactive conformation of the kinase or 
that directly interferes with drug binding. A large number of 
speciﬁ  c mutations have been characterized and tremendous 
effort has been put forth to develop more effective strategies 
to treat imatinib-resistant CML patients. Two novel kinase 
inhibitors, dasatinib (Sprycel™; Bristol-Myers Squibb) and 
nilotinib (Tasigna™; Novartis), have shown promising clini-
cal activity in some imatinib-refractory patients and both have 
recently earned FDA approval. Unfortunately, patients with 
the T315I BCR-ABL mutation do not respond to these new 
drugs (Kantarjian et al 2006; Talpaz et al 2006).
Given these considerations, a major focus in the ﬁ  eld of 
CML therapy is the development of novel strategies that can 
effectively treat T315I+ patients. Indeed, a large number of 
anticancer agents are under investigation for this speciﬁ  c 
indication. HDAC inhibitors are one such class of drugs 
that may have utility in the clinical treatment of imatinib-
resistant CML. HDAC inhibitors are a fascinating class of 
anticancer agents, due to their multifaceted mechanisms 
of action and preferential toxicity for malignant cells, and 
they have demonstrated promising anticancer activity in 
a number of pre-clinical and clinical studies (Kelly and 
Marks 2005). SAHA (suberoylanilide hydroxamic acid, 
vorinostat, Zolinza®; Merck) is the most clinically advanced 
HDAC inhibitor and recently received FDA approval for 
the treatment of cutaneous T-cell lymphoma (CTCL) in an Biologics: Targets & Therapy 2008:2(2) 203
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oral formulation. SAHA’s anticancer mechanism of action 
has been reported to include the induction of apoptosis, 
autophagy, polyploidy, reactive oxygen species (ROS), and 
growth inhibition (Yu et al 2003; Shao et al 2004; Xu et al 
2005; Nawrocki et al 2006).
Due to its ability to provide essential sources of energy, 
autophagy has been suggested to blunt the efﬁ  cacy of several 
pro-apoptotic therapeutic agents. Therefore, drugs that impair 
autophagy could theoretically potentiate the anticancer efﬁ  -
cacy of SAHA and other HDAC inhibitors by disabling this 
important cell survival mechanism. We recently tested this 
hypothesis in a cell line model of imatinib resistance and in 
imatinib-refractory primary CML cells from patients with 
BCR-ABL mutations, including T315I (Carew et al 2007). 
Both chloroquine (CQ) and 3-methyladenine (3-MA), two 
pharmacological inhibitors of autophagy, synergistically 
increased the killing power of SAHA against imatinib-
resistant CML. Furthermore, this therapeutic strategy was 
also effective in killing T315I-Bcr-Abl-expressing cells 
lacking p53, and this combination demonstrated a high 
degree of selectivity, indicating that a therapeutic index can 
be achieved.
CQ is a weak base and a known lysosomotropic agent 
that perturbs lysosomal function. Our data indicated that 
CQ synergizes with SAHA by disrupting the lysosomal 
membrane permeability of CML cells, which in turn led to 
the rapid relocalization and accumulation of the lysosomal 
aspartic protease cathepsin D to the cytosol. Notably, cathep-
sin D is a key mediator of a lysosomally triggered apoptotic 
cascade induced by several anticancer agents (Boya et al 
2003; Fehrenbacher and Jaattela 2005) and a key substrate 
of this protease is the antioxidant protein thioredoxin (Trx). 
Interestingly, the CQ/SAHA combination markedly reduced 
Trx levels in CML cells, and correspondingly increased ROS 
(Carew et al 2007), suggesting that a CQ-to-LMP-to-cathep-
sin D-to-Trx-to-ROS pathway contributes to the demise of 
imatinib-resistant CML also treated with SAHA.
Collectively, these ﬁ  ndings indicate that autophagy pro-
motes the survival of CML cells after metabolic stress that 
is induced by SAHA. Thus, inhibition of autophagy by CQ 
interferes with this cytoprotective response and augments 
SAHA’s anticancer activity. A recent study revealed that 
imatinib stimulates autophagy in a wide variety of cell types, 
suggesting that this response contributes to the resistance 
of several tumor types (Ertmer et al 2007). Thus, future 
investigations are clearly warranted to evaluate the impact 
of targeting the autophagy pathway on the anticancer activity 
of imatinib, where one would predict that inhibitors of 
autophagy such as CQ may also have utility in combination 
with imatinib (Figure 1). Indeed, inhibition of autophagy as 
a novel anticancer strategy may have broad applications for 
a wide variety of refractory malignancies. This concept is 
further supported by recent studies demonstrating that inhibi-
tion of autophagy by CQ in a Myc-driven mouse model of 
B cell lymphoma delays tumor onset (Maclean et al 2008) 
and augments the anticancer activity of the alkylating agent 
cyclophosphamide in established disease (Amaravadi et al 
2007). Indeed, clinical trials testing the efﬁ  cacy of hydroxy-
chloroquine in combination with bortezomib, temozolomide, 
temsirolimus, or other agents have been initiated for various 
malignancies. The knowledge gained from these trials will 
provide critical insights into the clinical potential of inhibi-
tion of autophagy as a novel anticancer strategy.
Figure 1 Targeting the autophagy pathway in CML. Imatinib-resistant BCR-ABL+ CML 
are sensitive to a therapeutic combination of SAHA, a FDA-approved HDAC inhibitor, 
and CQ, a FDA-approved anti-malarial agent (Carew et al 2007). Here the overall 
efﬁ  cacy of SAHA is thought to be compromised by its induction of the autophagy 
pathway, which is initiated by the formation of double-membraned autophagosomes 
from vesicular structures coined the phagophore. Autophagosomes deliver their cargo, 
bulk cytosolic material and organelles, to the lysosome, which degrades the cargo 
to provide essential building blocks and energy to the CML cell. The lysosomotropic 
agent CQ compromises lysosomal functions and thus derails the autophagy pathway, 
augmenting the killing power of SAHA to overcome imatinib resistance provoked by 
mutations in BCR-ABL and/or p53 (Carew et al 2007).
Abbreviations: CML, chronic myelogenous leukemia; CQ, chloroquine; HDAC, 
histone deacetylase; SAHA, suberoylanilide hydroxamic acid.
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Concluding remarks
Autophagy is an evolutionarily conserved cell survival path-
way that is now rightly receiving attention as a regulator of 
tumor cell biology. Recent investigations have suggested 
that autophagy is a promising target for pharmacological 
inhibition in the context of cancer therapy (Carew et al 2007; 
Amaravadi et al 2007). On the ﬂ  ip side, others have argued 
that autophagy represents an alternative cell death pathway 
that contributes to the killing power of certain anticancer 
agents (Kanzawa et al 2003; Takeuchi et al 2005). Despite 
these controversies, it is clear that agents such as CQ that 
inhibit autophagy may have clinical utility in the treatment 
of imatinib-refractory CML. The observations that imatinib 
alone induces autophagy, coupled with the evidence that 
autophagy may play an active role in resistance to anti-
cancer agents, mandates the need for additional studies to 
deﬁ  ne whether it represents a novel mechanism of imatinib 
resistance. It will also be very interesting to assess if ima-
tinib-refractory CML patients have higher basal rates of 
autophagy than those that respond well to therapy. Hopefully, 
the knowledge gained from such studies will enable clini-
cians to use the genetic status of key autophagy regulators to 
predict therapeutic responses and tailor speciﬁ  c regimens to 
optimize clinical outcomes for patients with CML, and for 
those suffering from other resistant malignancies.
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